Proud For Profits
  • Investing
  • Stock
  • Latest News
  • Economy
  • Investing
  • Stock
  • Latest News
  • Economy
No Result
View All Result
Proud For Profits
No Result
View All Result
Home Stock

Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

by
December 31, 2024
in Stock
0
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal

Investing.com — Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket trading Tuesday.

Following the termination, Sangamo regained the rights to develop the therapy and stated it would explore all possibilities to move the program forward, including seeking a new collaboration partner.

The end of the agreement delays Sangamo’s pathway to market, as Pfizer had been expected to submit data for potential regulatory approval of the therapy in early 2025.

Pfizer stated the decision followed a comprehensive review of clinical trial data, feedback from experts, and slow adoption of hemophilia A gene therapies among patients with moderate to severe disease. The company noted that interest in additional gene therapy options for this patient group is currently limited.

“We believe it is best to re-dedicate our time and resources to those assets and treatments that will have the greatest impact on patients and the greatest chance of commercial success,” Pfizer added.

Earlier this year, Pfizer disclosed late-stage trial results showing the therapy reduced annual bleeding episodes in patients with the condition.

The collaboration and license agreement will officially end on April 21, 2025, Sangamo said. Until then, trial participants will continue to be monitored as planned during the transition.

Hemophilia A affects approximately 25 in every 100,000 male births globally. The disorder results from a genetic defect that impairs the production of clotting factors, causing severe bleeding during injuries or surgeries.

Sangamo also noted it remains committed to advancing its therapy for Fabry disease, aiming to submit it for regulatory approval in the latter half of 2025.

Barclays (LON:BARC) analysts said Pfizer’s announcement sent a bearish view on hemophilia gene therapy commercial opportunity for Sangamo, but they view the stock sell-off as “overdone since limited valuation was assigned to HemoA program.”

The bank reiterated an Overweight rating on the stock, noting it expects a meaningful upside from near-term licensing deal on ST-920 in Fabry Disease.

Separately, TD Cowen analysts said they are “disappointed” in Pfizer’s unexpected decision, “given the competitive and likely approvable clinical data profile.”

“We believe PFE likely discontinued giro development given the commercial failure of Biomarin’s HemeA GTx Roctavian, whose launch suggests an extremely limited market for a HemeA GTx with 5-10 years of efficacy,” they added.

This post appeared first on investing.com
Previous Post

Huachen AI Parking Management Technology Holding Co Files for 1.5M Share IPO at $4-$6/sh

Next Post

4 reasons why the post-election S&P 500 rally has been losing steam: Yardeni

Next Post
4 reasons why the post-election S&P 500 rally has been losing steam: Yardeni

4 reasons why the post-election S&P 500 rally has been losing steam: Yardeni

Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Popular News

    How technology has changed inauguration coverage

    How technology has changed inauguration coverage

    January 20, 2025
    AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’

    AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’

    January 20, 2025
    Here’s How To Find The Best Upcoming Earnings Reports

    Here’s How To Find The Best Upcoming Earnings Reports

    January 20, 2025
    Track all markets on TradingView

    About Proud For Profits

    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Main Categories

    • Investing
    • Stock
    • Latest News
    • Economy

    Latest News

    • How technology has changed inauguration coverage
    • AOC launches series of explosive Instagram rants on eve of inauguration: ‘I don’t celebrate rapists’
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 proudforprofits.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Latest News
    • Economy

    Copyright © 2025 proudforprofits.com | All Rights Reserved